Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis

Inclusion Criteria:

- A woman of childbearing potential must have a negative urine pregnancy test
(beta-human chorionic gonadotropin) at screening and at Week 0

- Before randomization, a woman must be either: a) Not of childbearing potential:
premenarchal; postmenopausal (greater than [>] 45 years of age with amenorrhea for at
least 12 months or any age with amenorrhea for at least 6 months and a serum
follicle-stimulating hormone level (FSH) >40 International Units Per Liter [IU/L]);
permanently sterile (example, tubal occlusion, hysterectomy, bilateral salpingectomy);
or otherwise be incapable of pregnancy, b) Of childbearing potential and practicing a
highly effective method of birth control, consistent with local regulations regarding
the use of birth control methods for subjects participating in clinical studies:
example, established use of oral, injected or implanted hormonal methods of
contraception; placement of an intrauterine device (IUD) or intrauterine system (IUS);
barrier methods: condom or occlusive cap (diaphragm or cervical/vault caps) plus
spermicidal foam/gel/ film/cream/suppository (if available in their locale); male
partner sterilization (the vasectomized partner should be the sole partner for that
participant); true abstinence (when this is in line with the preferred and usual
lifestyle of the participant)

- Agree not to receive a Bacillus Calmette Guerin (BCG) vaccination during the study, or
within 12 months after the last administration of study drug

- Have a Psoriasis Area and Severity Index (PASI) greater than or equal to [>=] 12 at
screening and at baseline

- Have an involved body surface area (BSA) >= 10 percent (%) at screening and at
baseline

Exclusion Criteria:

- Has unstable cardiovascular disease, defined as a recent clinical deterioration (eg,
unstable angina, rapid atrial fibrillation) in the last 3 months or a cardiac
hospitalization within the last 3 months

- Has a history of lymphoproliferative disease, including lymphoma; a history of
monoclonal gammopathy of undetermined significance (MGUS); or signs and symptoms
suggestive of possible lymphoproliferative disease, such as lymphadenopathy or
splenomegaly

- Has a transplanted organ (with exception of a corneal transplant >3 months before the
first administration of study drug)

- Has a nonplaque form of psoriasis (example, erythrodermic, guttate, or pustular)

- Has received any anti-tumor necrosis factor alpha (TNF-alpha) biologic therapy within
3 months before the first administration of study drug